bluebird bio, Inc.

NasdaqGS:BLUE Stock Report

Market Cap: US$186.3m

bluebird bio Past Earnings Performance

Past criteria checks 0/6

bluebird bio has been growing earnings at an average annual rate of 18.9%, while the Biotechs industry saw earnings growing at 15% annually. Revenues have been declining at an average rate of 30.2% per year.

Key information

18.9%

Earnings growth rate

26.5%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-30.2%
Return on equity-41.0%
Net Margin-419.6%
Last Earnings Update30 Sep 2023

Recent past performance updates

Recent updates

bluebird bio Is Priced Below IP Value

Mar 23

Bluebird Bio: Innovative Therapies, Monetary Setbacks

Jan 25

Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?

Oct 13
Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?

Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation

Jul 13
Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation

Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo

Oct 04

Bluebird bio names interim finance chief

Sep 26

Bluebird bio jumps 17% on FDA approval of new gene therapy

Sep 19

bluebird bio' chief strategy and financial officer to depart

Sep 12

FDA approves bluebird bio's Zyntego beti-cel gene therapy for beta thalassemia

Aug 17

bluebird bio: Potential For 3 Gene Therapy Approvals In 12 Months Makes Buy Case

Jun 22

bluebird bio: Beaten Down Biotech With Possible Long-Term Potential

May 09

Bluebird Bio: Gene Therapy Launches Could Bring Big Revenues, Providing They Meet Approval

Feb 07

bluebird bio: Ticker Fueled By Gambling Chance Of Commercial Success

Dec 12

bluebird bio (NASDAQ:BLUE) Will Have To Spend Its Cash Wisely

Nov 08
bluebird bio (NASDAQ:BLUE) Will Have To Spend Its Cash Wisely

Revenue & Expenses Breakdown

How bluebird bio makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:BLUE Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2322-91149-52
30 Jun 239-96139-50
31 Mar 234-123137-31
31 Dec 224-2671370
30 Sep 225-431159178
30 Jun 226-507180125
31 Mar 225-56319070
31 Dec 214-5632100
30 Sep 21-238-5731870
30 Jun 21-220-6142170
31 Mar 21-21-4802300
31 Dec 200-5612400
30 Sep 20250-6422860
30 Jun 20240-6532840
31 Mar 2054-8282840
31 Dec 190-5552360
30 Sep 1954-7152490
30 Jun 1957-6552270
31 Mar 1951-6051990
31 Dec 1855-5561740
30 Sep 1840-5241500
30 Jun 1836-4571280
31 Mar 1845-3821080
31 Dec 1735-336940
30 Sep 1733-290810
30 Jun 1727-288720
31 Mar 1711-276690
31 Dec 166-264650
30 Sep 166-239630
30 Jun 166-205620
31 Mar 169-198550
31 Dec 1514-167460
30 Sep 1519-139360
30 Jun 1524-113290
31 Mar 1525-63240
31 Dec 1425-49230
30 Sep 1425-37230
30 Jun 1425-26200
31 Mar 1425-29170
31 Dec 1320-25140
30 Sep 1314-21120
30 Jun 138-15100

Quality Earnings: BLUE is currently unprofitable.

Growing Profit Margin: BLUE is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BLUE is unprofitable, but has reduced losses over the past 5 years at a rate of 18.9% per year.

Accelerating Growth: Unable to compare BLUE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BLUE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).


Return on Equity

High ROE: BLUE has a negative Return on Equity (-40.97%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.